|
목적 : Autologous serum eye dropsare considered a safe and efficient for treatment of dry eyes associated with Sjőgren syndrome (SS).The serum provides essential components to the ocular surface;however, when serum proinflammatory cytokine levels increase, such as in secondary SS, autologous serum eye drops may not be beneficial—especially in patients with severe ocular surface epitheliopathy. Thepurpose of this study was to comparethe clinical efficacies of autologous serum eye drops in the management of primary and secondary SS.
방법 : PrimarySS dry eye patients (n = 20; 35 eyes) and secondary SS dry eye patients (n = 14; 27 eyes). Serum concentrations of proinflammatory cytokines (tumor necrosis factor [TNF]-α,interleukin [IL]-1β, IL-6, and IL-8) were measured by a multiplex immunobead assay. The ocular symptom scores, ocular staining grades, and tear breakup time (tBUT) were evaluated before and after 4 weeks of 50% autologous serum eye drop application.
결과 : At enrollment,secondary SS patients had higher serum proinflammatory cytokine levels (TNF-α, IL-1β, IL-6, and IL-8) than primary SS patients (P < 0.01).After 4 weeks of autologous serum eye drop treatment, primary SS patients had significantly improved ocular symptoms (P < 0.01), ocular surface staining grades (P < 0.01), and tBUT (P < 0.05). However, secondary SS patients had no improvement (P > 0.05).
결론 : Our results suggest that autologous serum eye drops should be used judiciously by patients with higher serum proinflammatory cytokine levels such as those associated with secondary SS.
|